Basel Medical Group vs Newgenivf Group
Newgenivf Group is the larger business, with $23.7m of revenue in fiscal 2025 against $12.8m for Basel Medical Group (1.9 times as much). Newgenivf Group grew faster (336.3% against 49.9%). Newgenivf Group kept more of each dollar of sales as profit: a net margin of 41.7% against -4.5%. Newgenivf Group carries less debt relative to equity (16.4% against 190.8%).
| Latest fiscal year | Basel Medical GroupBMGL, 2026 | Newgenivf GroupNIVF, 2025 |
|---|---|---|
| Revenue | $12.8m | $23.7m |
| Revenue growth | 49.9% | 336.3% |
| Net income | −$582,757 | $9.9m |
| Operating margin | — | -45.2% |
| Net margin | -4.5% | 41.7% |
| Return on equity | -15.0% | 77.2% |
| Free cash flow | −$688,281 | −$11.1m |
| Cash | $409,464 | $758,621 |
| Total debt | $6.7m | $4.4m |
| Debt to equity | 190.8% | 16.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $8.2m | $202,122 |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 8 buys, 2 sales |